For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $1.84 in the prior trading day, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $1.86, up 1.09%. In other words, the price has increased by $1.09 from its previous closing price. On the day, 0.86 million shares were traded. ACRS stock price reached its highest trading level at $1.9 during the session, while it also had its lowest trading level at $1.83.
Ratios:
Our goal is to gain a better understanding of ACRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.88 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 201497920 and an Enterprise Value of 104057928. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.00 while its Price-to-Book (P/B) ratio in mrq is 1.53. Its current Enterprise Value per Revenue stands at 6.198 whereas that against EBITDA is -1.786.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.43, which has changed by 0.61739135 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 2.49%, while the 200-Day Moving Average is calculated to be 3.25%.
Shares Statistics:
The stock has traded on average 1.05M shares per day over the past 3-months and 955430 shares per day over the last 10 days, according to various share statistics. A total of 108.33M shares are outstanding, with a floating share count of 92.30M. Insiders hold about 14.81% of the company’s shares, while institutions hold 72.89% stake in the company. Shares short for ACRS as of 1757894400 were 5821942 with a Short Ratio of 5.55, compared to 1755216000 on 5982293. Therefore, it implies a Short% of Shares Outstanding of 5821942 and a Short% of Float of 6.4.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.51 and -$0.55 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.62, with 5.0 analysts recommending between -$0.41 and -$0.87.
Revenue Estimates
6 analysts predict $1.59M in revenue for. The current quarter. It ranges from a high estimate of $2.1M to a low estimate of $1M. As of. The current estimate, Aclaris Therapeutics Inc’s year-ago sales were $4.35MFor the next quarter, 6 analysts are estimating revenue of $1.57M. There is a high estimate of $1.97M for the next quarter, whereas the lowest estimate is $1M.
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.2M, while the lowest revenue estimate was $5.2M, resulting in an average revenue estimate of $6.34M. In the same quarter a year ago, actual revenue was $18.72MBased on 8 analysts’ estimates, the company’s revenue will be $5.05M in the next fiscal year. The high estimate is $10M and the low estimate is $900k.
